Known as the Tykerb Evaluation After Chemotherapy (TEACH), this study is also sponsored by the manufacturer. Dr.
这项被称为TEACH (Tykerb化疗后评估)的研究也是由生产商赞助的。
Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.
拉帕替尼能阻断肿瘤细胞生长的信号，进入细胞后能阻止HER2蛋白发挥作用。
The FDA approval of Tykerb was based on the results of a study involving approximately 400 breast cancer patients with advanced-stage HER2 disease.
FDA参照大约400例晚期her 2阳性的乳腺癌病例的研究结果的基础上，批准了拉帕替尼应用于临床。
According to the FDA, Tykerb inhibits tumor growth by going inside cells containing the HER2 protein and blocking signals that promote tumor growth.
根据FDA提供的资料，拉帕替尼通过进入表达HER2蛋白的细胞，阻滞促进肿瘤生长的信号。
As is standard procedure with all new drug approvals, the FDA worked with the drug's manufacturer to compose the instruction labeling accompanying Tykerb.
作为批准新上市的药物的一个标准程序，FDA将和药物开发公司撰写一个拉帕替尼的使用说明标签。
That study revealed that women who took Tykerb in combination with capecitabine were significantly more likely to respond positively to treatment and to experience a delay in tumor growth.
这个研究结果表明：服用拉帕替尼和卡培他滨获得更为显著地治疗效果，延迟了肿瘤的生长。
That study revealed that women who took Tykerb in combination with capecitabine were significantly more likely to respond positively to treatment and to experience a delay in tumor growth.
这个研究结果表明：服用拉帕替尼和卡培他滨获得更为显著地治疗效果，延迟了肿瘤的生长。
应用推荐